Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$27.34

0.22 (0.81%)

07:31
11/22/16
11/22
07:31
11/22/16
07:31

AstraZeneca resumes enrollment for head/neck cancer trials after hold lifted

AstraZeneca announced that the U.S. FDA has lifted the partial clinical hold on the enrollment of new patients with head and neck squamous cell carcinoma for clinical trials of durvalumab as monotherapy and in combination with tremelimumab or other potential medicines. The Phase 3 KESTREL trial has already re-opened for new patient enrollment at some clinical study sites and the EAGLE trial is expected to resume recruitment shortly, without amendments to either protocol. AstraZeneca will progressively resume enrollment for all HNSCC trials across the participating sites in the U.S. and globally, subject to national health authority and ethics committee approval where required. The status of active recruitment will be reflected on clinicaltrials.gov in the coming days. The partial clinical hold on new patient enrollment was communicated on October 27, after preliminary findings from ongoing clinical trials related specifically to head and neck cancer. The FDA lifted the partial clinical hold following a review of the comprehensive analysis provided by AstraZeneca of bleeding events that were observed as part of the routine safety monitoring of the Phase 3 KESTREL and EAGLE trials.

  • 16

    Feb

AZN AstraZeneca
$27.34

0.22 (0.81%)

10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.

TODAY'S FREE FLY STORIES

PHM

PulteGroup

$24.04

-0.24 (-0.99%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
PulteGroup initiated  »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$33.47

-0.5 (-1.47%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
D.R. Horton initiated  »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

$34.80

-0.34 (-0.97%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
CalAtlantic initiated  »

CalAtlantic initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$13.01

0.03 (0.23%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Beazer Homes initiated  »

Beazer Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$40.40

-0.4 (-0.98%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Meritage Homes initiated  »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Toll Brothers initiated  »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$52.41

-0.84 (-1.58%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Lennar initiated  »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.23

-0.1 (-0.45%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
KB Home initiated  »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MHK

Mohawk

$242.70

-0.22 (-0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Mohawk initiated  »

Mohawk initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$65.09

0.06 (0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Fortune Brands initiated  »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$34.60

-0.29 (-0.83%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$52.75

-1 (-1.86%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Installed Building Products initiated  »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.42

-0.85 (-1.26%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Owens Corning initiated  »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$195.16

1.35 (0.70%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Whirlpool initiated  »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$38.82

0.06 (0.15%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Masco initiated  »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEG

Leggett & Platt

$52.66

-0.16 (-0.30%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Leggett & Platt initiated  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USG

USG

$29.29

0.35 (1.21%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
USG initiated  »

USG initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSTE

Caesarstone

$35.20

1.05 (3.07%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Caesarstone initiated  »

Caesarstone initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

19:18
06/22/17
06/22
19:18
06/22/17
19:18
Hot Stocks
YouTube says reaches 1.5B monthly users »

In a blog post Thursday,…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AHH

Armada Hoffler

$13.70

-0.07 (-0.51%)

19:08
06/22/17
06/22
19:08
06/22/17
19:08
Downgrade
Armada Hoffler rating change  »

Armada Hoffler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

SBUX

Starbucks

$59.51

-0.45 (-0.75%)

18:59
06/22/17
06/22
18:59
06/22/17
18:59
Initiation
Starbucks initiated  »

Starbucks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

GPMT

Granite Point Mortgage

18:16
06/22/17
06/22
18:16
06/22/17
18:16
Syndicate
Granite Point Mortgage 10M share IPO priced at $19.50 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

TWO

Two Harbors

$10.39

0.02 (0.19%)

, GPMT

Granite Point Mortgage

18:15
06/22/17
06/22
18:15
06/22/17
18:15
Hot Stocks
Two Harbors to contribute commercial real estate assets to Granite Point »

Two Harbors Investment…

TWO

Two Harbors

$10.39

0.02 (0.19%)

GPMT

Granite Point Mortgage

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

GE

General Electric

$27.55

-0.23 (-0.83%)

18:05
06/22/17
06/22
18:05
06/22/17
18:05
Hot Stocks
Concept Laser, LAUAK sign LOI for additive manufacturing collaboration »

Concept Laser, a GE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 02

    Oct

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

18:05
06/22/17
06/22
18:05
06/22/17
18:05
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.